v3.26.1
Product Revenue (Tables)
 3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Net Product Revenue
The following table summarizes total other revenue recognized for the three months ended March 31, 2026 and 2025:
Three Months Ended
March 31,
20262025
Other Revenue$$
Amgen royalty revenue18,297 5,519 
Novartis broad markets revenue5,263 3,522 
Other2,549 (292)
Other Revenue26,109 8,749 
The table below presents the Company’s net product revenue for the three months ended March 31, 2026 and 2025:
 Three Months Ended
 March 31,
 20262025
 $$
Product revenue – gross1,893,489 1,400,066 
Less: rebates and sales returns(406,160)(291,536)
Product revenue – net1,487,329 1,108,530 
The following table disaggregates net product revenue by product for the three months ended March 31, 2026 and 2025:
 Three Months Ended
 March 31,
 20262025
 $$
BRUKINSA®
1,094,843 791,664 
TEVIMBRA®
206,241 171,164 
XGEVA®
89,920 70,423 
BLINCYTO®
34,035 23,906 
KYPROLIS®
16,971 19,728 
POBEVCY®
12,127 13,745 
Other33,192 17,900 
Total product revenue – net1,487,329 1,108,530 
Schedule of Accrued Revenue Rebates and Returns
The following table presents the roll-forward of accrued revenue rebates and returns for the three months ended March 31, 2026 and 2025:
 Rebates, Returns and Other DeductionsContra AR AccrualsTotal
 $$
Balance at December 31, 2025
398,533 79,126 477,659 
Accrual198,270 207,890 406,160 
Payments(156,366)(225,344)(381,710)
Balance at March 31, 2026
440,437 61,672 502,109 
Balance at December 31, 2024
235,600 50,699 286,299 
Accrual130,027 161,509 291,536 
Payments(105,683)(177,050)(282,733)
Balance at March 31, 2025
259,944 35,158 295,102